Epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) are now the therapy of choice for patients with EGFR-mutant non-small cell lung cancer (NSCLC). This evidence concerns the gene EGFR and non-small cell lung carcinoma.